Literature DB >> 3282124

Kidney pathology in liver allograft recipients after long-term treatment with cyclosporin A.

F E Dische1, J Neuberger, J Keating, V Parsons, R Y Calne, R Williams.   

Abstract

Organ transplant recipients given immunosuppressive treatment with cyclosporin A are at risk of injury due to nephrotoxicity. Eight liver allografted patients whose renal function became impaired during therapy with cyclosporin A for up to 4.5 years were investigated by renal biopsy. Ischemic changes in glomeruli were found to be greater than in controls, and there was focal tubular atrophy, but an excess of lesions in small arteries could not be demonstrated. In one patient there were glomerular changes suggestive of thrombotic microangiopathy. Interstitial fibrosis and cellular infiltration were slight. The pathogenesis of the ischemia remains to be elucidated, but reasons are advanced for favoring the view that the mechanism of cyclosporin A nephrotoxicity is primarily vasomotor, causing a reduction of renal blood flow and glomerular filtration rate without permanent organic arterial narrowing; nephrons become damaged irreversibly nevertheless.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3282124

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  6 in total

1.  The effect of FK 506 and CyA on the Lewis rat renal ischemia model.

Authors:  M A Nalesnik; H S Lai; N Murase; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

2.  Tacrolimus (FK506)-Associated Renal Pathology.

Authors:  Parmjeet S Randhawa; Thomas E Starzl; Anthony Jake Demetris
Journal:  Adv Anat Pathol       Date:  1997-07       Impact factor: 3.875

Review 3.  Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.

Authors:  A J Olyaei; A M de Mattos; W M Bennett
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

4.  Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation.

Authors:  O Pappo; H Ramos; T E Starzl; J J Fung; A J Demetris
Journal:  Am J Surg Pathol       Date:  1995-02       Impact factor: 6.394

Review 5.  Benefit-risk assessment of ciclosporin withdrawal in renal transplant recipients.

Authors:  Eric Thervet; Frank Martinez; Christophe Legendre
Journal:  Drug Saf       Date:  2004       Impact factor: 5.228

Review 6.  Sirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results.

Authors:  Eric Thervet
Journal:  Int J Nanomedicine       Date:  2006
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.